Suicide risk and efficacy of antidepressant drugs

Archives of General Psychiatry

Volumn 70, Issue 1, 2013, Pages 123-124

  Carroll, Bernard J ^a  

^a Pacific Behavioral Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; FLUOXETINE; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ATTENTION DEFICIT DISORDER; DEPRESSION; DRUG EFFICACY; DRUG INFORMATION; HUMAN; LETTER; RISK ASSESSMENT; RISK FACTOR; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; ADVERSE OUTCOME; ANXIETY DISORDER; NUMBERS NEEDED TO TREAT; PSYCHOMETRY; SUICIDE ATTEMPT; MAJOR DEPRESSION; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SUICIDE;

EID: 84872005443     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.756     Document Type: Letter

References (7)

1. Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):580-587.
2. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):572-579.
3. Safety and efficacy of atomoxetine or atomoxetine plus fluoxetine in the treatment of mixed attentional and affective disorders. Clinical study summary: study B4Z-MC-LYAQ. Lilly CT Registry ID#4668. Page 308. http://www.lillytrials. com/results/Strattera.pdf. Published 2005. Accessed November 12, 2012.
4. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915-924. (Pubitemid 41193203)
5. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
6. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043. (Pubitemid 47121392)
7. Vitiello B, Silva SG, Rohde P, Kratochvil CJ, Kennard BD, Reinecke MA, Mayes TL, Posner K, May DE, March JS. Suicidal events in the Treatment for Adolescents With Depression Study (TADS). J Clin Psychiatry. 2009;70(5):741-747.